Edwards Lifesciences exec trades 2,038 EW shares

Edwards Lifesciences Corp CVP, TAVR Daniel J. Lippis reported option exercises, tax withholding, and open-market sales of company stock.

Rhea-AI Filing Summary

Edwards Lifesciences Corp CVP, TAVR Daniel J. Lippis reported option exercises, tax withholding, and open-market sales of company stock. On May 1, 2026, he exercised employee stock options for 1,019 shares at $59.2567 per share and sold 1,000 shares at $82.9889 plus 19 shares at $83.9880. On May 4, 2026, he exercised options for another 1,019 shares at $59.2567 and sold 1,019 shares at $83.98. A separate 252-share disposition on May 3, 2026 covered tax obligations. After these transactions, he directly held about 33,681.9103 shares of Edwards Lifesciences common stock. The filing notes all reported trades were effected under a pre-arranged Rule 10b5-1 trading plan.

Insider Trade Summary 10b5-1

Exercise and Sale: 2,038 shares ($49K approx. pre-tax spread)

Exercise and Sale 8 txns

Insider Lippis Daniel J.

Role CVP, TAVR

Sold 2,038 shs ($170K)

Approx. gross sale proceeds $170K

Approx. exercise cost $121K

Approx. pre-tax spread $49K

Type	Security	Shares	Price	Value
Exercise	Employee Stock Option (Right to Acquire)	1,019	$0.00	$0.00
Exercise	Common Stock	1,019	$59.2567	$60K
Sale	Common Stock	1,019	$83.98	$86K
Exercise Price or Tax Liability	Common Stock	252	$83.98	$21K
Exercise	Employee Stock Option (Right to Acquire)	1,019	$0.00	$0.00
Exercise	Common Stock	1,019	$59.2567	$60K
Sale	Common Stock	19	$83.988	$2K
Sale	Common Stock	1,000	$82.9889	$83K

Holdings After Transaction: Employee Stock Option (Right to Acquire) — 0 contracts (Direct); Common Stock — 33,681.9103 shares (Direct)

Footnotes (3)

1. F1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 30, 2025.
2. F2. This transaction was executed in multiple trades at prices ranging from $83.980 to $84.095. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
3. F3. This transaction was executed in multiple trades at prices ranging from $82.540 to $83.490. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Key Figures

Shares sold: 2,038 shares Option exercise price: $59.2567 per share Sale price May 1 (block): $82.9889 per share +4 more

7 metrics

Shares sold 2,038 shares Net open-market sales in May 2026

Option exercise price $59.2567 per share Employee stock options exercised May 1 and May 4, 2026

Sale price May 1 (block) $82.9889 per share Sale of 1,000 shares on May 1, 2026

Sale price May 1 (additional) $83.9880 per share Sale of 19 shares on May 1, 2026

Sale price May 4 $83.98 per share Sale of 1,019 shares on May 4, 2026

Post-transaction holdings 33,681.9103 shares Direct common stock held after May 4, 2026 transactions

Tax-withholding shares 252 shares Tax-withholding disposition on May 3, 2026

Key Terms

Rule 10b5-1 trading plan, Employee Stock Option (Right to Acquire), tax-withholding disposition, open-market sale, +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted..."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Employee Stock Option (Right to Acquire) financial

"security_title: "Employee Stock Option (Right to Acquire)" with underlying common stock shares"

tax-withholding disposition financial

"transaction_action: "tax-withholding disposition" for the 252-share F-code transaction"

A tax-withholding disposition is an event or transaction—such as selling or transferring securities, exercising options, or receiving compensation—that triggers a requirement to hold back part of the payment and remit it to tax authorities. It matters to investors because it reduces the cash they receive immediately and can change the timing and amount of taxable income, like a cashier taking a portion of your sale proceeds to pay taxes before you get the rest.

open-market sale financial

"transaction_action: "open-market sale" for S-code common stock transactions"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

derivative exercise/conversion financial

"transaction_action: "derivative exercise/conversion" for M-code option exercises"

FAQ

What insider transactions did Edwards Lifesciences (EW) report for Daniel J. Lippis?

Edwards Lifesciences reported that Daniel J. Lippis exercised stock options for 2,038 shares and sold 2,038 shares of common stock in open-market transactions, along with a 252-share tax-withholding disposition, across several dates in May 2026.

At what prices did Daniel J. Lippis sell Edwards Lifesciences (EW) shares?

Daniel J. Lippis sold 1,000 Edwards Lifesciences shares at $82.9889, 19 shares at $83.9880, and 1,019 shares at $83.98. These sales followed option exercises and were reported as open-market or private transactions in the Form 4 filing.

What stock options did Daniel J. Lippis exercise in Edwards Lifesciences (EW)?

He exercised employee stock options covering 1,019 shares on May 1, 2026 and another 1,019 shares on May 4, 2026, each with a conversion or exercise price of $59.2567 per share, converting these options into Edwards Lifesciences common stock.

How many Edwards Lifesciences (EW) shares does Daniel J. Lippis hold after these Form 4 transactions?

Following the reported option exercises, sales, and tax-withholding disposition, Daniel J. Lippis directly holds 33,681.9103 shares of Edwards Lifesciences common stock, as disclosed in the post-transaction ownership figures for the most recent transaction date.

Were Daniel J. Lippis’s Edwards Lifesciences (EW) trades under a Rule 10b5-1 plan?

Yes. A footnote states the transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Daniel J. Lippis, indicating the trades were pre-arranged under that plan rather than timed discretionarily.

What is the 252-share disposition in the Edwards Lifesciences (EW) Form 4 for Daniel J. Lippis?

The Form 4 labels the 252-share transaction in Edwards Lifesciences common stock as a tax-withholding disposition, meaning shares were delivered to cover exercise price or tax liabilities rather than being sold in an open-market trade.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/04/2026 - 07:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lippis Daniel J.

(Last) (First) (Middle)

ONE EDWARDS WAY

(Street)

IRVINE CALIFORNIA 92614

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Edwards Lifesciences Corp [ EW ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CVP, TAVR

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/01/2026		M(1)		1,019	A	$59.2567	34,952.9103	D
Common Stock	05/01/2026		S(1)		19	D	$83.988(2)	34,933.9103	D
Common Stock	05/01/2026		S(1)		1,000	D	$82.9889(3)	33,933.9103	D
Common Stock	05/03/2026		F		252	D	$83.98	33,681.9103	D
Common Stock	05/04/2026		M		1,019	A	$59.2567	34,700.9103	D
Common Stock	05/04/2026		S		1,019	D	$83.98	33,681.9103	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Acquire)	$59.2567	05/01/2026		M			1,019	05/08/2020	05/07/2026	Common Stock	1,019	$0.0000	1,019	D
Employee Stock Option (Right to Acquire)	$59.2567	05/04/2026		M			1,019	05/08/2020	05/07/2026	Common Stock	1,019	$0.0000	0.0000	D

Explanation of Responses:

1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 30, 2025.

2. This transaction was executed in multiple trades at prices ranging from $83.980 to $84.095. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

3. This transaction was executed in multiple trades at prices ranging from $82.540 to $83.490. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.

	Linda J. Park, Attorney-in-Fact	05/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)